🔗 https://bit.ly/3FsFgOW It's her big game. You want to be there AND be fully present. Living with disease makes that difficult by holding you back. Over time, the sounds of disease - doctor visits, tests, managing medication, saying “no” to life’s most important moments - mute the joy of life. But what happens when you #SilenceDisease? #AmplifyLife #RNAi #RNAiTherapeutics
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 249,131 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-24), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
We’re growing our Commercial field team and have several key Business Account Executive roles open for those early in their sales career journey. If you have a "challenge accepted" mindset and are inspired by the chance to put patients first, work alongside passionate colleagues and shape the future of medicine, we want to connect! Featured Openings: 🔗 Midwest (Chicago) https://bit.ly/3Ksk1Px 🔗 Northwest (Seattle/Portland) https://bit.ly/467WD2q 🔗 Northern California (East Bay to Sacramento) https://bit.ly/4mlfRWW Learn more about our other open roles and what makes Alnylam a top employer: https://bit.ly/3Kas43t #ChallengeAccepted #BiotechJobs
-
-
Living with disease is noisy. Day-to-day life is filled with the sounds of endless doctor appointments, tests, managing medication and having to decline invitations to do the things you really want to do. Over time, these sounds mute the joy of life. But what happens when disease is silenced? Learn more: https://bit.ly/4iG8rw6 #SilenceDisease #AmplifyLife #RNAi #RNAiTherapeutics
-
Ziggy’s parents, Jackie and Colin, knew something wasn’t right. Their persistence helped lead to their newborn son’s diagnosis of primary #hyperoxaluria type 1 (#PH1), a genetic #raredisease. See how Jackie and Colin advocated for Ziggy: https://bit.ly/4077xSE
-
Healthcare Professionals: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed. Learn what to look for to better detect this #RareDisease. https://bit.ly/40UHIWa
-
This week at #RISE2025 in Madrid, we were proud to have Carol Pitcher-Towner, Head of Development Programs, represent our team on an industry panel focused on supporting gender equity in cardiovascular medicine. The day-long conference, taking place at European Society of Cardiology, connects women working in cardiology to share and build non-clinical skills that support professional development and career advancement. Carol shared her personal experience and insights with fellow leaders in the field. #ESCCongress #GenderEquity #womenincardiology
-
-
Healthcare Professionals: The burden of living with acute hepatic #porphyria (AHP) can greatly impact your patients’ quality of life. People living with AHP may have higher risk of long-term complications that have an immense emotional toll including depression and anxiety. Learn more about managing this #RareDisease. https://bit.ly/4nYBNJw
-
We're committed to educating the next generation of biopharmaceutical professionals. Our internship, co-op, and fellowship programs provide hands-on experience with cutting-edge RNAi science, business exposure, and skill development opportunities. These programs aren't just about learning - they're launching pads for successful careers in biotech. Ready to be part of the future of medicine? Learn more about our programs: https://bit.ly/4mgbyx3 #InternshipPrograms #RNAi
-
-
Did you know that sometimes, proteins your body makes can cause or contribute to disease? These proteins can be either be faulty, or healthy. RNAi therapeutics are a type of medicine, pioneered by Alnylam, that treats disease by targeting and disabling specific mRNA (messenger RNA) which tell your body how to make these unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science
-
Drug development is a long and perilous journey with a historically high failure rate. Advances in genomic sequencing and a more human-focused approach using genetic validation of disease targets are changing that. "Our focus on genetic validation has helped our drug candidates achieve a clinical trial success rate that's six times the industry average," says Paul Nioi, Alnylam's SVP of Discovery and Translational Research. Science curious to learn more? Read about how Alnylam and others who are embracing this approach are improving the speed and odds of success in drug development in this Nature Portfolio article (sponsored content): https://bit.ly/4hJnLbJ #RNAiTherapeutics #RNAinterference #RNAi #DrugDevelopment #genetics #genomics #biotechnology #pharmaceuticals #biopharma